The content on this site is intended for healthcare professionals only
Dr Gerhard Held speaks to ecancer about the interim analysis of the Niveau trial which is an international, randomised phase 3 study of the AGMT, GLA, HOVON, Lysa and PLRG.
The objective of this study was to evaluate the efficacy and safety of nivolumab added to R-GemOx in patients with R/R LBCL after 1 prior line of therapy not eligible for HDCT/HSCT owing to age and/or comorbidities.
The study found that the addition of nivolumab to R-GemOx and subsequent maintenance with nivolumab did not improve progression-free survival. However, there was a trend towards improved overall survival, suggesting that nivolumab may enhance the efficacy of subsequent therapies.
The study is ongoing with a final analysis scheduled after completion of follow-up.
SIOG 2024: Updates in haematology
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting
Understanding the remaining unmet needs in a post ASCT NDMM setting
Guiding transplant decisions in multiple myeloma with MRD
Encouraging results using mismatched unrelated donors in stem cell transplantation
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
